Health Catalyst (NASDAQ:HCAT) Price Target Cut to $1.50 by Analysts at Wells Fargo & Company

Health Catalyst (NASDAQ:HCAT) had its target price decreased by Wells Fargo & Company from $1.75 to $1.50 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s target price would suggest a potential downside of 15.49% from the stock’s current price.

Several other research firms have also recently weighed in on HCAT. Cantor Fitzgerald restated a “neutral” rating on shares of Health Catalyst in a research note on Monday, May 11th. Stephens reduced their price objective on Health Catalyst from $2.00 to $1.75 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. Citigroup lowered their target price on shares of Health Catalyst from $2.50 to $2.00 and set a “neutral” rating on the stock in a research note on Tuesday. Weiss Ratings raised shares of Health Catalyst from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. Finally, Canaccord Genuity Group increased their price objective on shares of Health Catalyst from $2.00 to $3.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. Four analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Health Catalyst has a consensus rating of “Hold” and a consensus target price of $2.93.

Health Catalyst Trading Down 0.8%

NASDAQ:HCAT opened at $1.77 on Thursday. The stock has a market cap of $133.59 million, a price-to-earnings ratio of -0.49 and a beta of 1.55. The company has a quick ratio of 1.69, a current ratio of 1.69 and a debt-to-equity ratio of 1.10. The company’s 50 day moving average price is $2.01 and its 200-day moving average price is $1.69. Health Catalyst has a 52 week low of $0.96 and a 52 week high of $3.80.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.01. The company had revenue of $70.49 million during the quarter, compared to analyst estimates of $69.09 million. Health Catalyst had a negative net margin of 90.61% and a negative return on equity of 1.57%. On average, equities research analysts forecast that Health Catalyst will post -0.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Health Catalyst

A number of institutional investors have recently bought and sold shares of HCAT. HighMark Wealth Management LLC boosted its position in shares of Health Catalyst by 139.0% in the fourth quarter. HighMark Wealth Management LLC now owns 741,482 shares of the company’s stock worth $1,772,000 after purchasing an additional 431,200 shares during the period. BlackRock Inc. bought a new position in Health Catalyst in the 2nd quarter worth $3,654,000. Deutsche Bank AG purchased a new stake in Health Catalyst in the 2nd quarter worth $43,000. Perigon Wealth Management LLC bought a new stake in Health Catalyst during the second quarter valued at about $77,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Health Catalyst in the second quarter valued at about $159,000. 85.00% of the stock is owned by institutional investors.

Health Catalyst Company Profile

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.